内科セミナーMET3 高脂血症

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,190 円(税込)

購入する

商品紹介

内科学の急速な進歩・発展は、細分化と専門化をもたらし、近年、ますますその度を深めております。それに伴い、臨床家に要求される知識の量は急増の一途をたどっており、質的にも知識のlife cycleはますます短縮し、日々新しい医学へと脱皮しているのが現状であります。このことは、専門外の知識・情報について疎遠になりがちなspecialistや、最新の情報を吸収しきれないgeneralistの増加という情況をうみ出しております。内科セミナーは、このような認識のもとに企画された内科治療全書であり、up to dateな知識・情報を、迅速に、かつ総合的に提供して、今日の要求に応えようとするものであります。

目次

  • 表紙
  • 執筆者
  • 目次
  • 1. 血清リポ蛋白の化学
  • §1 .血清脂質
  • I. コレステロール
  • 1. サポニンによる沈殿
  • 2. 酸試薬による呈色反応
  • II. グリセリド
  • III. リン脂質
  • IV. 遊離脂肪酸
  • §2. 血清リポ蛋白
  • I. 主要リポ蛋白の分類
  • II. キロミクロン
  • III. 超低比重リポ蛋白(VLDL)
  • 1. アポB
  • 2. アポC-I
  • 3. アポC-II
  • 4. アポC-III
  • 5. アポE(ARP)
  • IV. 低比重リポ蛋白(LDL)
  • V. 高比重リポ蛋白(HDL)
  • 1. アポA-I
  • 2. アポA-II
  • 3. アポDあるいはA-III
  • 4. アポF
  • 5. threonine-poor apoprotein
  • VI. その他のリポ蛋白
  • 1. Lp (a)
  • 2. リポ蛋白-X
  • 終りに
  • 文献
  • 2. 血清リポ蛋白の代謝
  • §1. リポ蛋白の生成
  • I. 脂質とアポ蛋白の生成
  • II. カイロミクロンの生成
  • III. VLDLの生成
  • IV. LDLの生成
  • V. HDLの生成
  • VI. その他のリポ蛋白の生成
  • §2. リポ蛋白の異化
  • I. 脂質成分およびアポ蛋白の交換と転送
  • II. リポ蛋白の異化に関与する酵素
  • 1. LCAT
  • 2. リポ蛋白リパーゼ
  • 3. 肝臓のリパーゼ
  • III. カイロミクロンの異化
  • IV. VLDLの異化
  • V. LDLの異化
  • 1. LDLレセプター
  • 2. EndocytosisとリソゾームによるLDL蛋白とコレステロールエステルの水解
  • 3. コレステロールおよびコレステロールエステルの生成の調節
  • 4. LDLレセプター活性の調節
  • VI. HDLの異化
  • 文献
  • 3. 高脂血症と血管変化
  • I. 高脂血症
  • 1. 血中脂質の存在様式
  • 2. 家族性高脂血症
  • 3. 二次性高脂血症
  • II. 高脂血症の動脈壁への作用
  • III. 高脂血症と血栓
  • IV. 凝固促進的血管内皮構造の変化
  • V. 動脈硬化の臨床
  • VI. 冠動脈硬化
  • VII. 大動脈硬化
  • VIII. 末梢閉塞性動脈硬化
  • IX. 粥状動脈硬化の診断
  • 結び
  • 文献
  • 4. 高脂血症の疫学
  • はじめに
  • §1. 栄義と血清脂質値
  • I. 発展途上国と米国の比較
  • II. イタリーおよび日本と米国の比較
  • III. 血清コレステロール値におよぼす食事中のコレステロールおよび脂肪酸の影響
  • IV. 血清トリグリセライド値におよぼす食事中の糖質の影響
  • §2. 日本人の血清コレステロール, トリグリセライドの正常値
  • I. 文部省班研究による健常日本人の血清コレステロールおよびトリグリセライド値
  • 1. 測定方法
  • 1) 血清コレステロール値
  • 2) 血清トリグリセライド値
  • 3) 採血時間の設定
  • 2. 研究対象
  • 3. 栄養調査
  • 4. データーの解析
  • 5. 結果
  • II. 健常日本人の血清コレステロール値の定次推移
  • §3. 日本人の高脂質血症の頻度
  • 文献
  • 5. 本態性高脂血症
  • §1. 概念
  • §2. 血清リポ蛋白の種類と組成
  • §3. 表現型による本能性高脂血症の分類：WHO分類
  • I. 概論
  • II. IIa型高脂血症とLDL-pathwayについて
  • III. IIa型高脂血症と動脈硬化
  • IV. IIa型高脂血症と黄色腫
  • V. 本態性高脂血症の各型とトリグリセライドリパーゼ(LPLとGL)
  • VI. 本態性高脂血症の各型とアポ蛋白, リポ蛋白代謝
  • VII. IV型高脂血症における肝細胞内VLDL代謝：Ultrastructural morphometry
  • §4. 家族性高脂血症の実例と解析
  • I. 家族性IIa型高脂血症
  • II. 家族性III型高脂血症
  • III. 家族性IV型(含IIb型)高脂血症
  • §5. 遺伝子型からみた高脂血症の分類
  • 文献
  • 6. 二次性高脂血症
  • §1. 肝胆道疾患
  • I. 肝臓と脂質代謝
  • 1. トリグリセリド(TG)
  • 2. リン脂質
  • 3. コレステロール
  • 4. 胆汁酸
  • II. 脂肪肝と高脂血症
  • III. 閉塞性黄疸
  • 1. 高脂血症の機序
  • 2. high density lipoprotein cholesterol
  • 3. LP-Xについて
  • 4. 高トリグリセリド血症
  • 5. 高コレステロール血症
  • IV. 胆石症
  • 文献
  • §2. 糖尿病
  • はじめに
  • I. インスリンの脂質代謝に及ぼす影響について
  • 1. インスリンの脂肪細胞に対する作用
  • 2. インスリンの肝に対する作用
  • 3. インスリンのトリグリセライド清澄化Clearanceに対する作用
  • 4. インスリンのHMG-Co Areductase活性に対する作用
  • II. 糖尿病とトリグリセライド代謝
  • 1. インスリン欠乏性の糖尿病に合併してみられるきわめて高度な高脂血症
  • 2. 糖尿症に合併する一般的なトリグリセライド血症
  • III. 糖尿病とコレステロール代謝
  • IV. 糖尿病患者の血漿リポタンパク異常について
  • おわりに
  • 文献
  • §3. 腎疾患
  • はじめに
  • I. 腎炎
  • II. 慢性腎不全
  • 1. 糖代謝
  • 2. 脂質代謝
  • III. ネフローゼ症候群
  • 1. 高コレステロール血症
  • 2. 高トリグリセリド血症
  • おわりに
  • 文献
  • §4. 内分泌疾患, その他
  • I. 甲状腺機能低下症
  • II. 生長ホルモンの異常
  • III. 副腎糖質ステロイド
  • IV. 妊娠, 経口薬
  • V. 代謝疾患
  • VI. アルコール
  • VII. 多発性骨髄腫および免疫異常
  • おわりに
  • 文献
  • 7. 高脂血症の治療
  • §1. 食事療法
  • はじめに
  • I. 高脂血症の診断基準
  • II. わが国の食生活の現況
  • III. 食事療法の実際
  • 1. 食事療法の基本原則
  • 2. 各タイプ別による食事療法
  • 1) Type I
  • 2) Type II
  • 3) Type III
  • 4) Type IV
  • 5) Type V
  • 3. アルコール摂取の問題
  • 1) アルコールの脂質代謝に及ぼす影響
  • 2) 我々の成績―いわゆるAlcohol induced hyperlipidema(アルコール起因性高トリグリセライド血症)
  • 4. われわれの行なっている高脂血症者の食事指導
  • おわりに
  • 文献
  • §2. 運動療法
  • はじめに
  • I. 正常者における運動負荷の影響
  • 1. 短期運動負荷の影響
  • 2. 長期運動負荷の影響
  • II. 運動処方の実際
  • おわりに
  • 文献
  • §3. 薬物療法
  • はじめに
  • I. 脂質低下剤の動脈硬化性疾患に対するprimary prevention
  • II. 脂質低下剤の動脈硬化性疾患に対するsecondary prevention
  • III. 脂質低下剤の種類
  • 1. Clofibrate
  • 2. Nicotinic Acid (Niacin, ニコチン酸)
  • 3. d-thyroxine
  • 4. cholestyramine
  • 5. Colestipol
  • 6. β-sistosterol
  • 7. Estrogen
  • 8. 蛋白同化ステロイドホルモン
  • 9. Heparinoid
  • 10. Neomycin
  • 11. Para-aminosalicylic acid (PAS)
  • 12. その他の脂質低下剤
  • おわりに
  • 文献
  • 8. リポ蛋白欠損症
  • §1. 先天性低脂血症
  • I. Tangier病
  • II. 無β-リポ蛋白血症
  • III. 低β-リポ蛋白血症
  • 文献
  • §2. 家族性LCAT欠損症
  • I. LCATの性質
  • II. LCAT活性の測定法
  • 1. Stokke-Norum法
  • 2. Glomest & Wright法
  • 3. ガス液体クロマトグラフィー法
  • III. LCATとリポ蛋白代謝
  • IV. LCAT欠損症
  • 1. 血清脂質およびリポ蛋白について
  • 2. 臨床所見
  • V. リポ蛋白異常症とLCAT活性
  • むすび
  • 文献
  • 9. リピドーシス, ムコポリサッカリドーシス
  • §1. リピドーシス
  • I. GM1-gangliosidoses
  • 1. 臨床症候
  • 1) 1型
  • 2) 2型
  • 2. 診断
  • 1) 1型
  • 2) 2型
  • II. GM2-gangliosidoses
  • 1. 臨床所見
  • 1) Tay-Sachs病
  • 2) Sandhoff病
  • 3) Juvenile GM2-gangliosidoses
  • 2. 診断
  • 1) Tay-Sachs病
  • 2) Sandhoff病
  • 3) Juvenile GM2-gangliosidoses
  • III. Fabry病
  • 1. 臨床症候
  • 2. 診断
  • 3. 治療
  • IV. Gaucher病
  • 1. 臨床症候
  • 1) 1型(成人型あるいは慢性型)
  • 2) 2型(急性神経型あるいは若年型)
  • 3) 3型(亜急性神経型あるいは若年型)
  • 2. 診断
  • V. Niemann-Pick病
  • 1. 臨床症候
  • 1) A型(乳児型, 急性神経型)
  • 2) B型(慢性型, 非神経型)
  • 3) C型(慢性神経型)
  • 4) D型(Nova Scotia型)
  • 5) E型(成人型, 非神経型)
  • 2. 診断
  • VI. 異染性脳白質ジストロフィー
  • 1. 臨床症候
  • 1) 幼児型
  • 2) 若年型
  • 3) 成人型
  • 2. 診断
  • VII. Krabbe病 (globoid cell leukodystrophy)
  • 1. 臨床症候
  • 1) 乳児型
  • 2) 遅発型
  • 2. 診断
  • VIII. Farber病 (lipogranulomatosis)
  • 1. 臨床症候
  • 2. 診断
  • §2. ムコポリサッカリドーシス
  • I. 概念と病因
  • 1. 定義
  • 2. MPSの種類と分布
  • 3. MPSのくりかえし構造の不均一性
  • 4. 成因
  • II. MPS症の臨床症状と診断
  • 1. MPS I
  • 1) MPS IH (Hurler症候群)
  • 2) MPS IH/S (Hurler-Scheie compound)
  • 3) MPS IS (Scheie症候群)
  • 2. MPS II (Hunter症候群)
  • 1) MPS IIA (Hunter症候群, severe)
  • 2) MPS IIB (Hunter症候群, mild)
  • 3. MPS III (Sanfilippo症候群)
  • 4. MPS IV (Morquio症候群)
  • 5. MPS VI (Maroteaux-Lamy症候群)
  • 1) MPS VIA (classic form)
  • 2) MPS VIB (mild form)
  • 6. MPS VII (β-glucuronidase欠損症)
  • 1) 臨床症候
  • 2) 診断
  • III. リピドーシスおよびムコポリサッカリドーシスの治療と予防
  • 文献
  • 索引
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1. 血清リポ蛋白の化学

P.23 掲載の参考文献
1) Allain, C.C., et al.:Clin.Chem., 20, 470, 1974.
PubMed
○"Blood lipids and lipoproteins:Quantitation, composition and metabolism", Ed.by Nelson, G.J., Wiley-Interscience, New York, 1972.
 
○Jackson, R.L, et al.:Physiol.Rev., 56, 259, 1976.
PubMed
2) Noma, A.& Nakayama, K.:Clin.Chem., 22, 336, 1976.
PubMed
○Morrisett, J.D., et al.:Biochim.Biophys.Acta, 472, 93, 1977.
PubMed
3) Noma, A., et al.:Clin.Chem., 24, 1504, 1978.
 
○Kane, J.P.:Plasma lipoproteins:Structure and metabolism, in"Lipid metabolism in mammals", Ed.by Snyder, F., p.209, Plenum Press, New York, 1977.
 
4) Noma, A., et al.:Atherosclerosis, 32, 327, 1979.
PubMed
5) Sata, T., et al.:Proc.Natl.Acad.Sci.U.S.A., 73, 1063, 1976.
PubMed
○Smith, L.C., et al.:Ann.Rev.Biochem., 47, 751, 1978.
PubMed
6) Patch, W., et al.:J.Biol.Chem., 253, 4911, 1978.
 
7) Steele, Jr.J.C.H.& Reynolds, J.A.:J.Biol.Chem., 254, 1633, 1979.
 
8) Triplett, R.B.& Fisher, W.R.:J Lipid Res., 19, 478, 1978.
 
9) Jackson, R.L., et al.:J.Biol.Chem., 249, 5308, 1974.
PubMed
10) Shulman, R.S., et al.:J.Biol.Chem., 250, 182.1975.
PubMed
11) Jackson, R.L., et al.:J.Biol.Chem., 249, 5314, 1974.
PubMed
12) Ganesan, D.& Bass, H.B.:FEBS Lett., 53, 1, 1975.
PubMed
13) Jackson, R.L., et al.:Proc.Natl.Acad.Sci.U.S.A., 74, 1942, 1977.
PubMed
7') Kane, J.P., et al.:Proc.Natl.Acad.Sic.U.S.A., 77, 2465, 1980.
 
14) Kinnunen, P.K., et al.:Proc.Natl.Acad.Sci.U.S.A., 74, 4848, 1977.
PubMed
15) Breckenridge, W.C., et al.:Circulation, 54 (Supp1) II-25, 1976.
 
16) Shelburne, F.A.& Quarfordt, S.H.:J.Biol.Chem., 249, 1428, 1974.
PubMed
17) Utermann, G.:Hoppe-Seyler`s Physiol.Chem., 356, 1113, 1975.
 
18) Shore, B.& Shore, V.:Biochem.Biophys.Res.Commun., 58, 1, 1974.
PubMed
19) Anderson, D.W., et al.:Atherosclerosis, 29, 161, 1978.
PubMed
20) Stoffel, W., et al.:Prcc.Natl.Acad.Sci.U.S.A., 71, 3696, 1974.
 
14') Smith, L.C., et al.:Ann.N.Y.Acad.Sci., 348, 213, 1980.
PubMed
21) Assmann, G.& Brewer, Jr.H.B.:Proc.Natl.Acad.Sci.U.S.A., 71, 1534, 1974.
 
22) Jackson, R.L., et al.:Mol.Cell.Biochem., 6, 43, 1975.
PubMed
23) Verdery III R.B.& Nichols, A.V.:Chem.Phys.Lipids, 14, 123, 1975.
 
24) Brewer, Jr.H.B., et al.:Biochem.Biophys.Res.Commun., 80, 623, 1978.
 
25) Kostner, G.M.:Biochim.Biophys.Acta, 336, 383, 1974.
 
26) McConathy, W.J.& Alaupovic, P.:FEBS Lett, 37, 178, 1973.
PubMed
27) Olofsson, S.O., et al.:Biochemistry, 17, 1032, 1978.
PubMed
28) Shore, V.G., et al.:Biochemistry, 17, 2174, 1978.
PubMed
29) Hauser, H., et al.:Biochim.Biophys.Acta, 489, 247, 1977.
PubMed

2. 血清リポ蛋白の代謝

P.40 掲載の参考文献
1) Jackson, R.L, J.D.Morrisett and A.M.Gotto, Jr.:Physiol.Rev.56:259-316 (1976)
 
2) Smith, L.C., H.J.Pownall and A.M.Gotto, Jr.:Ann.Rev.Biochem.47:751-777 (1978)
 
3) Rodwell, V.W., J.L.Nordstrom and J.J.Mitschelen:Adv.Lipid Res.14:1-74 (1976)
 
4) Cardell, R.R.Jr., S.Badenhausen and K.R.Porter.:J.Cell Biol.34:123-155 (1967)
 
5) Ockner, R.K.and K.J.Isselbacher:Rev.Physiol.Biochem.Pharmacol.71:107-146 (1974)
 
6) Friedman, H.I.and R.R.Cardell, Jr.:Exptl.Cell Res.75:57-62 (1972)
 
7) Mayes, P.A.:"Review of Physiological Chemistry" 16th Ed.(ed.H.A.Harper, V.W.Rodwell and P.A.Mayes) p.305, Lange Medical Publications, Los Altos, California (1977)
 
8) Eisenberg, S.and R.I.Levy:Adv.Lipid Res.13:1-89 (1975)
 
9) Windmueller, H.G., P.N.Herbert and R.I.Levy:J.Lipid Res.14:215-223 (1973)
 
10) Hamilton, R.L., M.C.Williams, C.J.Fielding and R.J.Havel.:J.Clin.Invest.58:667-680 (1976)
 
11) Forte, T., A.Nichols, J.Glomset and K.Norum:Scand.J.Clin.Lab.Invest.33 (Suppl.137):121-132 (1974)
 
12) Sabesin, S.M., H.L.Hawkins, L.Kuiken and J.B.Ragland:Gastroenterology 72:510-518 (1977)
 
13) Green, P.H.R., A.R.Tall and R.M.Glickman:J.Clin.Invest.61:528-534 (1978)
 
14) Manzato, E., R.Fellin, G.Baggio, S.Walch, W.Neubeck and D.Seidel:J.Clin.Invest.57:1248-1260 (1976)
 
15) Felker, T.E., R.L.Hamilton and R.J.Havel:Proc.Natl.Acad.Sci.USA 75:3459-3463 (1978)
 
16) Havel, R.J., J.P.Kane and M.L.Kashyap:J.Clin.Invest.52:32-38 (1973)
 
17) Albers, J.J., V.G.Cabana and Y.D.B.Stahl:Biochemistry 15:1084-1086 (1976)
 
18) Olivecrona, T., G.Bengtsson, S.-E.Marklund, U.Lindahl and M.Hook:Fed.Proc.36:60-65 (1977)
 
19) Kinnunen, P.K., R.L.Jackson, L.C.Smith, A.M.Gotto, Jr.and J.T.Sparrow:Proc.Natl.Acad.Sci.USA 74:4848-4851 (1977)
 
20) Carlson, L.A.and D.Ballantyne:Atherosclerosis 23:563-568 (1976)
 
21) Steinberg, D.:"Atherosclerosis III" (ed.G.Schettler and A.Weizel) p.658, Springer-Verlag, Berlin (1974)
 
22) Patsch, J.R., A.M.Gotto, Jr., T.Olivecrona and S.Eisenberg:Proc.Natl.Acad.Sci.USA 75:4519-4523 (1978)
 
23) Eisenberg, S.and D.Rachmilewitz:J.Lipid Res.16:341-351 (1975)
 
24) Sniderman, A.D., T.E.Carew, J.G.Chandler and D.Steinberg:Science.183:526-528 (1974)
 
25) Goldstein, J.L.and M.S.Brown:Ann.Rev.Biochem.46:897-930 (1977)
 
26) Gianturco, S.H., A.M.Gotto, Jr., R.J.Jackson, J.R.Patsch, H.D.Sybers,O.D.Taunton, D.L.Yeshrun and L.C.Smith:J.Clin.Invest.61:320-328 (1978)
 
27) Catapano, A.L., S.H.Gianturco, P.K.J.Kinnunen, S.Eisenberg, A.M.Gotto, Jr.and L.C.Smith:J.Biol.Chem.254:1007-1009 (1979)
 
28) Mahley, R.W.and T.L.Innerarity:"Drugs, Lipid Metabolism, and Atherosclerosis" (ed.D.Kritchevsky, R.Paoletti and W.L.Holmes) p.99-127 Plenum Publishing Corp., New York (1978)
 
29) Margolis, S.and D.Capuzzi:"Blood Lipids and Lipoproteins:Quantitation, Composition, and Metabolism" (ed.G.J.Nelson) p.825-880, Wiley-Interscience, New York (1972)
 
30) Blum, C.B., R.I.Levy, S.Eisenberg, M.Hall, III, R.H.Goebel and M.Berman:J.Clin.Invest.60:795-807 (1977)
 
31) Nakai, T., P.S.Otto, D.L.Kennedy and T.F.Whayne, Jr.:J.Biol.Chem.251:4914-4921 (1976)
 
32) Van Berkel, T.J.C.and A.Van Tol;Biochim.Biophys.Acta 530:299-304 (1978)
 
33) Miller, N.E., D.B.Weinstein and D.Steinberg:J.Lipid Res.18:438-450 (1977)
 
34) Carew, T.E., R.P.Saik, K.H.Johansen, C.A.Dennis and D.Steinberg:J.Lipid Res.17:441-450 (1976)
 
35) Gwynne, J.T.and B.Hess:Metabolism.27:1593-1600 (1978)
 
36) Andersen, J.M.and J.M.Dietschy:Biochem.Biophys.Res.Commun.72:880-885 (1976)
 

3. 高脂血症と血管変化

P.63 掲載の参考文献
1) 関本 博, 島田修史, 中西正人, 中田 勲:最新医学, 36:793, 1981.
Medical*Online
2) 山元寅男:脈管学, 18:5, 1978.
 
3) J.L.Goldstein and M.S.Brown:Ann Rev Biochem.46:897 (1977)
 
4) J.L.Goldstein and M.S.Brown:Amer J Med, 58:143 (1975)
 
5) N.Simionesuc, M.Simionescu and E.Palade:J Cell Biol, 64:586 (1975)
 
6) R.R.Bruns and G.E.Palade:JBiol, 37:244 (1968)
 
7) R.W.Wissler:JAtheroscler Res, 8:201 (1968)
 
8) O.Stein, L.Sangor, G.Zajicek andY.Stein:Paroi Arterielle, 1:187 (1973)
 
9) 黒住武史, 住吉昭信, 田中健蔵:動脈硬化, 1:193 (1974)
 
10) 関本 博:日内会誌, 69:1250 (1980)
 
11) 高野達哉, 今中常雄:細胞, 10:18 (1978)
 
12) Poller, L., Thomson, J.M.and Thomas, W.:Brit Med J, (1971)
 
13) 亀山正邦:日医会誌, 72:1 (1974)
 
14) 岡田了三:内科, 21:404 (1968)
 
15) 田中健三:血栓症1, 文光堂 (1977)
 

4. 高脂血症の疫学

P.88 掲載の参考文献
1) Walker, A.R.P.and Arvidsson, U.B.:J.Clin.Invest., 33:1358, 1954.
 
2) Higginson, J.and Pepler, W.J.:J.Clin.Invest., 33:1366, 1954.
PubMed
3) Brock, J.F.and Bronte-Stewart, B.:Arteriosclerosis in African Populations.p.102, Minneapolis, Minnesota Heart Association and University of Minnesota, 1956.
 
4) Keys, A., et al.:J.Clin.Invst., 35:1173, 1956.
 
5) Scrimshaw, N.S., et al.:Circulation, 15:805, 1957.
PubMed
6) Mann, G.V., Munoz, J.A.and Scrimshaw, N.S.:A, m.J.Med., 19:25, 1955.
 
7) Tejada, G.and Gore, I.:Am.J.Path., 33:887, 1957.
 
8) Stamler, J.:J.Nat.Med.Assoc., 50:161, 1958.
 
9) Stamler, J.:J.Am.Dietet.Assoc., 34:701, 814, 929, 1053, 1060, 1958.
 
10) Keys, A.:J.A.M.A., 164:1912, 1957.
 
11) Keys, A.:Diet and Coronary Heart Disease, World Trends in Cardiology:ICardiovascular Epidemiology, p.135, New York, Hoeber-Harper, 1956.
 
12) 八杉忠男:日内誌, 48:209, 1959.
 
13) Ahrens, E.H.Jr., et al.:Lancet, 1:115, 1959.
PubMed
14) Bronte-Stewart, B., et al.:Lancet, 2:1103, 1955.
 
15) Keys, A., et al.:Lancet, 2:959, 1957.
 
16) Keys, A., et al.:Metabolism, 14:1965.
 
17) Hegsted, D.M., et al.:Am.J.Clin.Nutr., 17:281, 1965.
PubMed
18) 秦 葭哉:慶応医学, 46:77, 1969.
 
19) Anderson, J.T.:Am.J.Clin.Nutr., 20:168, 1967.
PubMed
20) Hatch, F.T., et al.:Am.J.Med., 19:48, 1955.
 
21) Macdonald, I.and Braithwaite, D.M.:Clin.Sci., 27:23, 1964.
 
22) 五島雄一郎・他:日老医会誌, 3:295, 1966.
 
23) Research Committee on Atherosclerosis in Japan;Jap.Circul.J., 29:505, (1965).
 
24) Research Committee on Hyperlipidemia in Japan:動脈硬化, 1:101, 1973.
 
25) 大島研三.他:綜合臨牀, 13:1752, (1964).
 
26) Keys, A., et al.:J.Clin.Invest., 29:1347, (1950).
 
27) Lewis, L.A., et al.:Circulation, 16:227, (1957).
PubMed
28) Lund, E., et al.:Lancet, 11:1383, (1961).
 
29) 秋山房雄:日老医誌, 16:209, 1979.
 
30) 葛谷文男, 吉峰徳:日本臨床, 33:3169, 1975.
 
31) 八杉忠男:医事新報, 2845, 3:1978.
 
32) Brown, D.F., et al.:Circulation, 47:558, 1973.
PubMed
33) Wood, P.D.S., et al.:Circulation, 45:114, 1972.
 
34) 八杉忠男:臨床生理, 2:246, 1972.
 
35) 五島雄一他:内科, 22:812, 1968.
 
36) 葛谷文男:日老医誌, 16:217, 1979.
 

5. 本態性高脂血症

P.127 掲載の参考文献
1) Beaumont, J.L., Carlson, L.A., Cooper, G.R.et al:Classification of hyperlipidemias and hyperlipoproteinemias.Bull WHO.43:891-915, 1970.
PubMed
2) Fredrickson, D.S., Levy, R.I.& Lees, R.S.:Fat transport in lipoproteins:An integrated approach to mechanisms and disorders.N.Engl.J.Med.276:34-44, 94-103, 148-156, 215-225, 273-281, 1967.
 
3) Havel, R.J.:Pathogenesis, differentiation and management of hypertriglyceridemia.Adv.Intern.Med.15:117-154, 1969.
PubMed
4) Goldstein, J.L.& Brown, M.S.:Binding and degradation of low density lipoproteins by cultured human fibroblasts:Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia.J.Biol.Chem.249:5153-5162, 1974.
PubMed
5) Goldstein, J.L.& Brown, M.S.:Atherosclerosis:The low density lipoprotein receptor hypothesis.Metabolism 26:1257-1275, 1977.
PubMed
6) Packard, C.J., Third, J.L.H.C., Shepherd, J.et al.:Low density lipoprotein metabolism in a family of familial hypercholesterolemic patients.Metabolism 25:995-1006, 1976.
 
7) Hoff, H.F., Bradley, W.A., Heideman, C.L.et al.:Characterization of low density lipoprotein-like particle in the human aorta from grossly normal and atherosclerotic regions.Biochim.Biophys.Acta 573:361-374, 1979.
PubMed
8) Goldstein, J.L, Anderson, R.G.W., Buja, L.M.et al.:Overloading human aortic smooth muscle cells with low density lipoprotein-cholesteryl esters reproduces features of atherosclerosis in vitro.J.Clin.Invest.59:1196-1202, 1977.
 
9) 秦葭哉:黄色腫とリポタンパク代謝異常, 脂質代謝異常のすべて (高橋善弥太編), 南江堂, 1979, pp.302-321.
 
10) Mabuchi, H., Tatami, R., Haba, T.et al.:Achilles tendon thickness and ischemic heart disease in familial hypercholesterolemia, Metabolism 27:1672-1679, 1978.
PubMed
11) Greten, H., DeGrella, R., Klose, G.et al.:Measurement of two plasma triglyceride lipases by an immunochemical method:studies in patients with hypertriglyceridemia.J.Lipid Res.17:203-210, 1976.
PubMed
12) Augstin, J., Freeze, H., Boberg, J.et al.:Human postheparin plasma lipolytic activities.In Lipoprotein Metabolism, ed.by Greten, H., Springer-Verlag, Berlin-Heidelberg-New York, 1976, pp.7-12.
 
13) Kashyap, M.L., Srivastava, L.S., Chen, C.Y.et al.:Radioimmunoassay of human apolipoprotein C H.A study in normal and hypertriglyceridemic subjects.J.Clin.Invest.60:171-180, 1977.
 
14) Berman, M., Hall, M., Levy, R.I.et al.:Metabolism of apo B and apo C lipoproteins in man:kinetic studies in normal and hyperlipoproteinemic subjects.J.Lipid Res.19:38-56, 1978.
 
15) Breckenridge, W.C., Little, J.A., Steiner, G.et al.:Hypertriglyceridemia associated with deficiency of apo lipoprotein C-II.N.Engl.J.Med.298:1265-1273, 1978.
 
16) Langer, T., Strober, W.& Levy, R.I.:The metabolism of low density lipoprotein in familial type H hyperlipoproteinemia.J.Clin.Invest.51:1528-1536, 1972.
 
17) Levy, R.I., Billheimer, D.W.& Eisenberg, S.:The structure and metabolism of chylomicrons and very low density lipoproteins (VLDL).In plasma lipoproteins, ed.by Smellie, R.M.S., Academic Press, New York, 1971, pp.3-17.
 
18) Streja, D., Kallai, M.A.& Steiner, G.:The metabolic heterogeneity of human very low density lipoprotein triglyceride.Metabolism 26:1333-1344, 1977.
PubMed
19) Maruhama, Y., Ohneda, A., Tadaki, H.et al.:Hepatic steatosis and the elevated plasma insulin level in patients with endogenous hypertrigly ceridemia.Metabolism 24:653-664, 1975.
 
20) Maruhama, Y., Abe, R., Okuguchi, F.et al.:Interactions of obesity and glucose-stimulated insulin secretion in familial hypertiglyceridemia.Diabetes 27:682-693, 1978.
 
21) 奥口文宣, 阿部隆三, 丸浜喜亮, 後藤由夫:日本臨床代謝学会記録.第XVI集178-180, 1979.
 
22) Mabuchi, H., Tatami, R., Haba, T.et al.:Homozygous familial hypercholesterolemia in Japan.Am.J.Med.65:290-297, 1978.
PubMed
23) Glueck, C.J., Fallat, R.W., Mellies, M.J.et al.:Pediatric familial type III hyperlipoproteinemia.Metabolism 25:1269-1274, 1976.
PubMed
24) Hazzard, W.R., O'Donnell, T.F.& Lee, Y.L:Broad β disease (type III hyperlipoproteinemia) in a large kindred.Ann.Intern.Med.82:141-149, 1975.
 
25) 丸浜喜亮:肥満症における脂肪肝および高脂質血症, 脂質代謝異常のすべて (高橋善弥太編), 南江堂, 1979, pp.230-242.
 
26) Goldstein, J.L., Schrott, H.G., Hazzard, W.R.et al.:Hyperlipidemia in coronary heart disease, II.genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia, J.Clin.Invest.52:1544-1568, 1973.
PubMed
27) Brunzell, J.D., Schrott, H.G., Motulsky, A.G.et al.:Myocardial infarction in the familial forms of hypertriglyceridemia.Metabolism 25:313-320, 1976.
PubMed

6. 二次性高脂血症

P.140 掲載の参考文献
1) 菊地三郎ほか:脂肪肝の臨床, 日本医事新報, 2679号, 8-12, 1975.
 
2) 加藤活大ほか:脂肪肝の臨床的研究-とくに糖代謝の面から-日消誌, 71:32-40, 1974.
 
3) Seidel, D.et al.:A lipoprotein characterizing obstructive jaundice.J.Clin.Invest.48:1211-1223, 1969.
PubMed
4) Seidel, D.et al:Further aspects on the characterization of high and very low density lipoproteins in patients with liver disease.Europ.J.Clin.Invest.2:359-364, 1972.
PubMed
5) Quarfordt, S.H.et al.:Effect of biliary obstruction on canine plasma and biliary lipids.Lipids.8:522-530, 1973.
PubMed
6) Papadopoulos, N.M, Charles, M.A.:Serum lipoprotein patterns in liver disease.Proc.Soc.Exp.Med.Biol.134:797-799, 1970.
PubMed
7) Eder, H.A.et al.:Protein-lipid relationships in human plasma:In biliary cirrhosis, obstructive jaundice, and acute hepatitis.J.Clin.Invest.34:1147-1162, 1955.
PubMed
8) Fredrickson, D.S.et al.:The metabolic basis of inherited disease.Stanbury et al.編 McGraw-Hill book Comp.N.Y.1972.p.494.
 
9) Blomhoff, J.P.:High density lipoproteins in cholestasis.Scand.J.Gastroent.6:591-596, 1974.
PubMed
10) Seidel, D., Gretz, H., Ruppert, C.:Significance of the LP-X test indifferential diagnosis of jaundice.Clin.Chem.19:86-91, 1973.
 
11) Ritland, S.:Quantitative determination of abnormal lipoprotein of cholestasis, LP-X, in liver disease.Scand.J.Gastroenterology.10:5-15, 1975.
 
12) Magnani, H.N., Alaupovics, P.:Utilization of the quantitative assay of lipoprotein X in the differential diagnosis of extrahepatic obstructive jaundice and intrahepatic disease.Gastroenterology.71:87-93, 1976.
 
13) Klose, G.et al.:Secondary hypertriglyceridemia in patients with parenchymal liver disease.Europ.J.Clin.Invest.7:557-562, 1977.
PubMed
14) Mifller, P.et al.:Hypertriglyceridemia secondary to liver disease.Europ.J.Clin.Invest.4:419-428, 1974.
 
15) Small, D.M., Rapo, S.:Source of abnormal bile in patients with cholesterol gallstones.New Engl.J.Med.283:53-57, 1970.
PubMed
16) Vlahcevic, Z.R., Bell, C.C., Swell, L.:Significance of the liver in the production of lithogenic bile in man.Gastroenterology.59:165-173, 1970.
 
17) Caldwell, F.T., Levitsky, K.:The gallbladder and gallstone formation.Annals Surg.166:753-758, 1967.
 
18) 山本章, 垣内義亨:胆道疾患の病態生理.胆石症を中心として.胆汁脂質と血清リポ蛋白異常.日内会誌, 66:1209-1211,1977.
 
7-a) Hamilton, R.L.et al.:Cholestasis:Lamellar structure of the abnormal human serum lipoprotein.Science.172:475-478, 1971.
 
8-a) 内藤周幸:閉塞性黄疸時のリポ蛋白の変化-特にリポ蛋白Xを中心として-石川玉態編, 閉塞性黄疸, 102-110, 医歯薬出版, 東京, 1977.
 
P.151 掲載の参考文献
1) Bagdade, J.D.et al.:Diabetic lipemia.A form of acquired fat-induced lipemia.N.Engl.J.Med.276:427, 1963.
 
2) Brunzell, J.D.et al.:Evidence for diabetis mellitus and genetic forms of hypertriglyceridemia as independent entities.Metabolism 24:1115, 1975.
 
3) Fredrickson, D.S.:Hyperlipoproteinemia with carbohydrate intolerance:in Fajans, S.S.and Sussman, K.E.(Ed.):Diabetes mellitus:Diagnosis and treatment, Vol.3.Amer.Diab.Ass.Inc., New York, 1977, p.377.
 
4) Garcia, M.J.et al.:Morbidity and mortality in diabetics in the Framingham population.Diabetes 23:106, 1974.
 
5) Lewis, B.et al:Plasma triglyceride and fatty acid metabolism in diabetes mellitus.Europ.J.Clin.Invest.2:445, 1972.
PubMed
6) Lopes-Virella, M.F.L.et al.:Serum high density lipoprotein in diabetic patients.Diabetologia 13:285, 1977.
 
7) Nikkilta, F.A.et al.:Postheparin plasma lipoprotein lipase and hepatic triglyceride lipase in diabetes mellitus.Diabetes 26:11, 1977.
 
8) Nikkila, E.A.and Kekki, M.:Plasma triglyceride transport Kinetics in diabetes mellitus.Metabolism 22:1, 1973.
PubMed
9) Olefsky, J.M.et al.:Reappraisal of the role of insulin in hypertriglyceridemia.Amer.J.Med.57:551, 1974.
PubMed
10) Pykalisto,O.J.et al.:Determinations of human adipose tissue lipoprotein lipase.J.Clin.Invest.56:1108,1975.
PubMed
11) Reckless,J.P.D.et al:High-density and low density lipoprotein and prevalence of vascular disease in diabetes melitus.Brit.Med J,1:883,1978
 
12) Saudek, C.O D.and Eder, H.A.:Lipid metabolism in diabetes mellitus.Amer.J.Med.66:843, 1979.
 
13) Wahl, P.et al.:Diabetes und Hyperlipoproteinamien.Dtsch.Med.Wschr.99:2158, 1974.
 
14) 小坂樹徳:糖尿病の臨床, 日内会誌66:1, 1977.
 
15) 村勢敏郎:脂質代謝と酵素 (1) リポタンパクリパーゼ:内科シリーズNo.34.脂質代謝異常のすべて, 南江堂p.24, 1979.
 
P.165 掲載の参考文献
1) 最上武夫:腎疾患における脂質代謝に関する臨床的並びに実験的研究, 東京医誌, 68:405-444, 1960.
 
2) Defronzo, R.A.:Pathogenesis of Glucose intolerance in uremia, Metabolism, 27:1866-1880, 1978.
PubMed
3) Ferrannini, E., et al:The Response to intravenous glucose of Patients on maintenance hemodialysis.Metabolism, 28:125-135, 1978.
 
4) Rubenfeld, S.& Garber, A.J.:Abnormal carbohydrate metabolism in chronic renal failure.J.Clin.Inv.62:20-28, 1978.
 
5) Soman, V.and Felig, P.:Glucagon and Insulin binding to liver membranes in a partially nephrectomized uremic rat model.J.Clin.Inv.60:224-232, 1977.
 
6) Davidson, M.B., et al.:Effect of protein intake and dialysis on the abnormal growth hormone, Glucose and insulin homeostasis in uremia, Metabolism, 25:455-464, 1976.
PubMed
7) Norbeck, H., et al.:Serum lipid and lipoprotein concentrations in chronic uremia.Acta.Med.Scand.200:487-492, 1976.
PubMed
8) Ponticelli, C., et al:Lipid abnormalities in maintenance dialysis patients and renal transplant recipients.Kid.Int.13:suppl 8, 72-78, 1978.
 
9) Bagdade, J.D., et al.:Hyperlipidemia in renal failure;studies of plasmalipoproteins, hepatic triglyceride production, and tissue lipoprotein lipase in a chronically uremic rat model.J.Lab.& Clin.Med.91:176-186, 1978.
 
10) Heuck, C.C., et al.:Hyperlipoproteinemia in experimental renal insufficiency in the rat.Kid.Int.14:142-150, 1978.
 
11) Bolzano, K., Krempler, F.and Sandhofer, F.:Hepatic and extrahepatic triglyceride lipase activity in uraemic patients on chronic haemodialysis.Europ.J.Clin.In-V.8:289-293, 1978.
 
12) Murase, T., et al.:Inhibition of lipoprotein lipase by uremic plasma.A possible cause of hyper triglyceridemia.Metabolism, 24:1279-1286, 1975.
 
13) Lutz, W.:The influence of strongly basic uremic peptide on liberation of lipoprotein lipase activity from human adipose cells.Acta.Med.Pol.17:55-70, 1976.
PubMed
14) Staprans, I., Felts, J.M.and Zacherle B.:Apoprotein composition of plasma lipoproteins in uremic paients on hemodialysis.Clin.Chem.Acta.93:135-143, 1979.
 
15) Guarnieri, G.F., et al.:LCAT activity in chronic uremia.Kid.Int.13, suppl.8:26-30, 1978.
 
16) Huttunen, J.K., et al.:Lipoprotein metabolism in patients with chronic uremia Acta Med.Scand.204:211-218, 1978.
PubMed
17) Bagdade, J.D.:Uremic lipemia.A unrecognized abnormality in triglyceride production and removal.Arch.Int.Med.126:875-881, 1970.
 
18) Sanfelippo, M.L., Swenson, R.S.and Reaven, G.M.:Response of plasma triglycerides to dielary change in patients on hemodialysis.Kid.Int.14:180-186, 1978.
 
19) 平沢由平:腎不全における脂質代謝障害.治療学.2:457-463, 1979.
 
20) Edwards, K.D.G.:Antilipaemic drugs and nephrotic hyperlipidemia.Prog.Biochem.Pharmacol.7:370-426, 1972.
 
21) 八杉忠男ほか:腎疾患と高脂血症.Geriatric Medicine., 9:70-77, 1971.
 
22) Gherardi, E., et al:Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome.Europ.J.Clin.Invest.7:563-570, 1977.
PubMed
23) 吉利和, 内藤周幸:ネフローゼ症候群における高脂血症の成因, 日本臨床.26:1106-1116.1968.
Medical*Online
24) Goldberg, A.C.K., et al.:Origin of hypercholesterolemia in chronic experimental nephrotic syndrome.Kid.Int.
 
25) 伊藤昌孝:ネフローゼ症候群におけるlecithin, の活性に関する研究, 日老医誌.6:420-427,
 
26) Bridgman, J.F., et al.:Insulin and growth nephrotic syndrome.Q.J.Med.
PubMed
27) Shafrif, E.and Brenner, T.:Lipo-protein synthesis in hypoproteinemia of experimental nephrotic syndrome and plasmapheresis.Plasma Protein Turn over, ed by R.Bianchi, et al.:Macmillan, London-Basing stoke.p.343-353, 1976
 
28) Marsh, J.B.and Sparks, C.E.:Hepatitic lipoprotein secretion in puro mycin aminonucleoside nephrosis, Kid.Int.13:742, 1978.
 
29) Khano, et al.Studies in lipogenesis in the nephrotic syndrome produced in rats with the aminonucleosideof puromycin.Clin Sci.Mol.Med.53:49, 1977.
 
30) de Mendoza, S.G., drome, Metabolism, 25:1143-1149, 1976.
 
31) Tashimo, M., Matsuda, I.:Insulin and epinephrine sensitivity of isolated fat cells in experimental nephrosis.Clin.Chem.Acta.41:67-74, 1972.-74, 1972.
 
P.175 掲載の参考文献
1) Schwandt, P.:Die sekundaren Hyperlipoproteinaemie.Muench.Med.Wshr.115:644-649, 1973.
 
2) Loeb, J.N.:Hypothyroidism, Metabolic changes.in The Thyroid (ed.Werner, S.C.and Ingbar, S.H.) Harpers & Row, Hagerstown, 4th ed.1978, p.872-877.
 
3) Porte, D.Jr.,O:Hara, D.D., Williams, A.H.:Relation between post.heparin lipolytic activity and plasma triglycerides in myxoedema.Metabolism, 15:107-113, 1966.
 
4) Hazzard, W.R., Bierman, E.L.:Aggreviation of broad-B-disease by hypothyroidism.Arch.Int.Med.,130:322-330,1972.
 
5) Adlersberg, D., Schaffner, L, Drachman, S.R.:Developement of hypercholesterolemia during cortisone and ACTH therapy.J.Am.Med Ass., 144:909-914, 1950.
 
6) Sandhofer, F.:Plasma lipide bei Stoerungen der Schilddruesenfunktiondes Menschen.Klin.Wshr., 44:433-436, 1966.
 
7) Arons, D.L, Schreibman, P.H., Downs, P., Braveman, L.E., Arky, R.A.:Decreased postheparin-lipolytic activity in Graves:disease.New Engl.J.Med., 286:233-237, 1972.
 
8) Aloia, J.F., Roginsky, M S., Field, R.A.:Absence of hyperlipidemiain acromegaly, J.Clin.Endocri.Metab., 35:921-923, 1972.
 
9) Nikkila, E.A., Pelkonen, R.:Serum lipids in acromegaly.Metabolism, 24:829-838, 1975.
PubMed
10) Merimee, T.J., Hollander, W., Fineberg, S.E.:Studies of hyperlipidemiain the HGH-deficient state.Metabolism, 21:1053-61, 1972.
 
11) El-Shaboury, A.H., Hayes, T.M.:Hyperlipidemia in asthmatic patients receiving long-term steroid therapy.Brit.Med.J., 2:85-6, 1973.
PubMed
12) Bagdade, J.P., Porte, D.Jr., Bierman, E.L.:Steroid induced lipemia.A complication of high dosage corticoateroid therapy.Arch.Int.Med., 125:129-134, 1970.
 
13) de Alvarez, R.R., Goodell, B.W.:Serum lipid partitions and fatty acid composition (using gas chromatography) in gynecological cancer.Am.J.Obst.Gynecol., 88:1039-1062, 1964.
 
14) de Alvarez, R.R., Goodell, B.W., Zighelboim, I.:Fatty acid composition of serum lipid in pregancy and gynecological cancer.Am.J.Obstet.Gynecol, 97:419-442, 1967.
 
15) Knopp, R.H., Warth, M.R.:Lipoprotein changes in pregancy:adistict endogenous hypertriglyceridemia.J.Clin.Invest., 52, 48 a, 1973.
 
16) Hillman, L., Schonfeld, G., Miller, G.P., Wulff, G.:Apolipoproteins in human pregancy.Metabolism, 24:943-952, 1975.
 
17) Rossner, S., Larsson-Cohen, U., Carlson, L.A., Boberg, J.:Effect of an oral contraceptive agent on plasma lipids, plasma lipoprotein, the intraveous fat tolerancne and the postheparin-lipolytic activity.Acta med.Scand., 190:301-305, 1971.
 
18) Applebaum, D.M., Goldberg, A.P., Pykaelistlo,O.J., Brunzell, J°D., Hazzard, W.R.:Effect of estrogen on postheparin-lipolytic activity.Selective decline in hepatic triglyceride lipase.J.Clin.Invest., 59:601-608, 1977.
 
19) Zorrilla, E..Hules, M., Hernandez, A., Gershberg, H.:Severe endogenous hypertriglyceridemia during treatment with estrogen and oral contraceptives.J.Clin.Endocri., Met., 28:1793-1796, 1968.
 
20) Davidoff, F., Tishler, S., Rosoff, C.:Hyperlipidemia and pancreatitis associated with oral contraceptive therapy.New Engl.J.Med., 289:552-555, 1973.
PubMed
21) Moltch, M.E., Oill, P., Odell, W.D.:Massive hyperlipidemia during estrogen therapy.J.Am.Med.Ass., 227:522-527, 1974.
 
22) Teddeini, L., Karen, L., Nordstrom, L, Watson, C.J.:Hyper cholesterolemia in experimental and human hepatic porphyria.Metabolism, 13:691-701, 1964.
 
23) Lees, R.S., Song, C.S., Levere, R.D., Kappas, A.:Hyper-beta-lipo proteinemia in acute intermittent porphyria.New Engl.J.Med., 282:432-3, 1970.
 
24) Darlington, L.G., Scott, J.T.:Plasma lipid level in gout.Ann.Rheum.Dis.,:31:487-489, 1972.
PubMed
25) Mertz, D.P., Babucke, G.:Die Dyslipoproteinemie bei primaerer Gicht.Dtsch.Med.Wshr., 98:1457-1457, 1976.
 
26) 石川俊次:高脂血症と高尿酸血症との関連に関する研究動脈硬化, 3:367-371, 1976.
 
27) Wiedemann, E., Rose, H.G., Schwartz, E.:Plasma lipoprotein, glucose toelrance and insulin response in primary gout.Am.J.Med., 53:299-307, 1972.
 
28) Chait, A., Mancini, M., February, A.W., Lewis, B.:Clinical and metabolic study of alcoholic hypertriglyceridemia.Lancet H, 62-64, 1972.
 
29) Carlson, L.A.:cited from 28.
 
30) Taskinen, M.R., Nikkila, E.A.:Nocturnal hypertriglyceridemia and hyperinsulinnemia following moderate evening intake of alcohol.Acta Med.Scand., 202:173-177, 1977.
PubMed
31) Gross, W., Vetter, H., Juchems, Die alkoholinduzierte Hyperlipaemie.Muench.Med.Wshr., 111:2493-2496, 1969.
 
32) Lasowsky, M.S., Johnes, D.P., Davidson, C.S., Lieber, C.S.:Studies of alcoholic hyperlipidemia and its mechanism.Am.J.Med., 35:794-803, 1963.
 
33) Barona, E., Lieber, C.S.:Effect of chronic ethanol feeding on serum lipoprotein metabolism in the rat.J.Clin.Invest..49:769-778, 1970.
 
34) Oezer, F.L, Telatar, H., Talatar, F., Muetueoglu, E.:Monoclonal gammopathy with hyperlipidemia.Am.J.Med., 49:841-4, 1970.
 
35) Cohen, L., Blaisdell, R.K., Djordjerich, J., Ormister, V., Dobrilovic, J.:Familial xanthomatosis and hyperlipidemia and myelomatosis.Am.J.Med., 40:299-317, 1966.
 
36) Stern, M.P., Kolterman,O.G., McDeritt, H., Reaven, G.M.:Acquired type 3 hyperlipoproteinemia.Arch.Int.Med., 130:317-321, 1972.
 
37) Glueck, C.J.:Acquired type I hyperlipoproteinemia with systemic lupus erythematosus dysglobulinemia and heparin resistance Am.J.Med., 47:318-324, 1969.
PubMed
38) Glueck, C.J., Kaplan, A.P., Levy, R.I., Greten, H., Grlnick, H., Fredrickson, D.S.:A new mechanism of endogenous hypertriglycerldemia.Ann.Int.Med., 71:1051-1062, 1969.
 
39) Lewis, L.A., DeWolfe, V.G., Butkus, A., Page, I.H.:Autoimmune hyperlipidemia in a patient.Am.J.Med., 59:298-214, 1975.
 

7. 高脂血症の治療

P.197 掲載の参考文献
1) アメリカにおける血漿脂質ならびにリポ蛋白測定法の標準化, 医学のあゆみ.94:211, 263, 313, 359, 653, 765, 807, 1975.
 
2) Fredrickson, D.S., Levy, R.I.:Familial Hyperlipoproteinemia, The Metabolic Basis of Inherited Disease (Standburg, J.B., et al., ed.), 3rd ed New York:McGray-Hill, 545, 1972.
 
3) 中川昌一, 渡辺卓二:正常値, 異常値;血清, コレステロール, 綜合臨牀, 27:2159, 1978.
 
4) 渡辺卓二, 中川昌一:糖尿病と脂質代謝異常, 臨床病理.24:211, 1976.
 
5) 国民栄養の現状, 昭和50年国民栄養調査成績, 厚生省公衆衛生局栄養課編, 31, 1978.
 
6) 五島雄一郎:脂質代謝異常の臨床, 南山堂, 東京, 1977.
 
7) Levy, R.I., et al.:Dietary and Drug Treatment of Primary Hyperlipo proteinemia.77:267, 1972.
 
8) Mallov, S.:Effect of ethanol intoxication on plasma free fatty acids in rat.Quart.J.Stud.Alcohol 22:250, 1961.
PubMed
9) Brodie, B.B.and Maickel, R.P.:Role of sympathetic nervous system in drug induced fatty livers.Ann.New York Acad.Sc.104:1049, 1963.
 
10) Elko, E.E., Wooles, W.R.and DiLuzio, N.R.:Alterations and mobilizations of lipids in acute ethanol-treated rats.Am.J.Physiol 201:923, 1961.
 
11) Lieber, C.S., et al:Effect of ethanol on plasma free fatty acids in man.J.Lab.Clin.Med.59:826, 1962.
 
12) Schapiro, R., Drummay, G.D., Scheig, R., Mendelson, J.H.and Isselbaacher, K.J.,:Abnormalities of lipid transport accompanying Prolonged alcohol ingestion in man.Gastroenterology 44:849, 1963.
 
13) Zieve, L.:Jaundice, hyperlipemia and hemolitic anemia:heretofore unrecognized syndrome associated with alcoholic fatty liver and cirrhosis.Ann.Int.Med.48:471, 1958.
 
14) Ginsberg, H., Olefsky, J., Farquhar, J.W.and Reaven, G.M.:Moderate Ethanol Ingestion and Plasma Triglyceride Levels.Ann.Int.Med.80:143, 1974.
PubMed
15) Mendelson, H.J.:Alcohol-induced hyperlipidemia and beta lipoproteins.Sciens 18:1372, 1973.
 
16) Hanai, T., Wood, P., Michaels, G.and Kinsell, L.:Gel Chromatography of hyperlipidemic plasma on 2% agarose.Pro.Soc.Exp.Biol.Med.129:226, 1968.
 
17) Southgate, D.A.T.et al.:Metabolic responses to dietary supplements of bran.Metabolism 25:1129, 1976.
 
P.204 掲載の参考文献
1) Hoak, J.C., et al.:Toxic effect of glucagon induced acute lipid mobilization in geese.J.Clin.Invest., 47:2701, 1968.
PubMed
2) Oliver, M.f., et al.:Relation between Serum free-fatty-acids and arrythmias and death after acute myocardial infarction.Lancet, 710 April 6, 1968.
 
3) Wheathey, C.E.:Hyperventilation Syndrom;A frequent cause of chest pain.Chest, 68:195, 1975.
 
4) 小野三嗣:いわゆる健康体における運動ストレスの研究.日本医師会雑誌, 81:643, 1979.
 
5) Wahren, J., Felig, P.and Ahlborg, G.:Glucose Metabolism during Leg Exercise in Man.J.Clin.Invest.50:2715,1971.
 
6) Unger, R.M.:Glucagon and the Insulin:Glucagon Ration in Diabetes and other Catabolic Illness.Diabetes 20:834, 1971.
 
7) Felig, P.and Wahren, J.:Amino acid Metabolism in Exercising man.J.Clin.Invest., 50:2703, 1971.
 
8) Sanders, C., Levinson, G.E.:Effect of Exercise on The peripheral utilization of Glucose in Man.The New Eng.J.Med.271:220, 1964.
PubMed
9) Fahlen, M., Strenberg, J.and Bjorntorp, P.:Insulin Secretion in Obesity after Exercise.Diabetologia 8:141, 1972.
 
10) Hurter, R., et al.:Some immediate and long-team effects of exercise on the plasma lipid.Lancet 30:671, 1972.
 
11) Holloszy, J.O., et al.:Effect of a six month progam of endurance exercise on the serum lipids of middle-aged men.Am.J.Cardiol, 14:753, 1964.
 
12) Oscai, L.B.and J.A.Patterson:Normalization of serum triglyceride and lipoprotein electrophoretic pattern by exercise.Am.J.Cardiol., 30:775, 1972.
 
13) 運動療法:阿部正和, 小野三嗣編集, 267, 1978.
 
P.218 掲載の参考文献
1) A co-operative trial in the primary prevention of ischemic heart disease using clofibrate.Report from the Committee of Principal Investigators.Brit.Heart J., 40:1069, 1978.
 
2) Leild, B., Angelin, B and Einarsson, K.:Biliary lipid composition during treatment with hypolipidemic drugs.In Proceedings of 6th International Symposium on Drugs Affecting Lipid Metabolism.Ed.by D.Kritchevsky and W.Holnes.Plenum Press, New York (in press) 1978.
 
3) Sturdevant, R.A.L., Pearce, M.L.and Dayton, S.:Increased prevalence of cholelithiasis in men ingesting a serum cholesterol lowering diet.New Eng.J.Med.288:24, 1973.
 
4) Krasno, L.R., et al.:Clofibrate in coronary heart disease.Effect on morbidity and mortality.J.A.M.A., 219:845, 1972.
PubMed
5) Dewar, H.A.and Oliver, M.:Secondary prevention trials using clofibrate:A joint commentary on the New Castle and Scottisch trial Brit.Med.J., 41784, 1971.
 
6) The Coronary Drug Project.J.A.M.A., 214:1303, 1970.
PubMed
7) The Coronary Drug Project.J.A.M.A., 220:996, 1972.
PubMed
8) The Coronary Drug Project.J.A.M.A., 226:652, 1973.
PubMed
9) The Coronary Drug Project.Clofibrate and Niacin in Coronary heart disease.J.A.M.A., 231:360, 1975.
 
10) Thorp, J.M.and Waring, W.S.l Modification of metabolism and distribution of lipids by ethyl CPIB.Nature (Lond) 194:948, 1962.
 
11) Levy, R.L, Morganroth, J.and Rifkind, B.M.:Treatment of hyperlipidemia.New Eng.J.Med.290:1295, 1974.
 
12) Grundy, S.M., Ahrens, E.H.and Salen, G.:Mode of action Atromid Son cholesterol metabolism in man.J.Clin.Invest.48:330, 1969.
 
13) Levy, R.I.(Moderator), Discussants:Dietary and drug treatment of primary hyperlipoproteinemia.NIH Conference.Ann.Intern.Med.77:267, 1972.
 
14) Langer, T.and Levy, R.I.:Acute muscular syndrome associated with administration of Clofibrate.New Eng.J.Med.279:856, 1968.
 
15) Carlson, L.A.and Ostman, J.:Effect of nicotinic acid on plasma lipids in patients with hyperlipidemia during the first week of treatment.J.Athero.Res.8:667, 1968.
 
16) Anderson, R., Harhon, L.and Lundholm, L:Inhibition of cyclic AMP formation and lypolysis in rat adipose tissue by nicotinic acid.Athero sclerosis 18:399, 1973.
 
17) Owens, J.C.Neeley, W.B.and Owen, W.R.:Effect of sodium Dthyroxine in patients receiving anticoagulants New Eng.J.Med.266:76, 1962.
 
18) Tennent, D.M., Siegel, H.and Zaretti, M.E.:Plasma cholesterol lower.ing action of bile acids binding polymer in experimental animals.J.Lipid Res.1:467, 1960.
 
19) Haskin, S.A.and Van Itallie, T.B.:Cholestyramine resin therapy for hypercholesterolemia, clinical and metabolic studies.J.A.M.A.192:289, 1965.
 
20) Farquahr, J.W., Smith, R.E., Dempsly, M.:The effect of beta sitosterol on the serum lipids of young men with atherosclerotic heart disease.Circulation 14:77, 1956.
 
21) Best, M.M.and Duncan, C.H.:Modification of abnormal serum lipid patterns in atherosclerosis by administration of sitosterol.Ann.Intern.Med.45:614, 1956.
PubMed
22) Bhattacharyya, A.K., Connor, W.E.:Beta sitosterolemia and xanthomatosis.J.Clin.Invest.53:1033, 1974.
PubMed
23) Sachs, B.A.and Wolfam, L.:Effect of oxandralone on plasma lipids and lipoproteins of patients disorder of lipid metabolism.17:400, 1968.
 
24) Glueck, C.J.:Effect of oxandralone on plasma triglyceride and PHLA in patients with types III, IV and familial Hyperlipoproteinemia.Metabo-lism 20:691, 1971.
 
25) Samuel, P.and Steiner, A.:Effects of neomycirl on serum cholesterol level in man.Proc.Soc.Exp.Biol.Med.100:193, 1959.
PubMed
26) Samuel, P., Holtzman, C.M.and Meilman, E.:Effect of neomycin on exchangeable pools of cholesterol in the steady state.J.Clin.Invest.47:1806, 1968.
 
27) Lees, R.S.and Wilson, D.E.:The treatment of hyperlipidemia.New Eng.J.Med.284:186, 1971.
 
28) Barter, P.J., Conner, W.E., et al.:Lowering of serum cholesterol and triglyceride by para-amino-salicylic acid in hyperlipoproteinemia.Ann.Intern.Med.81:619, 1974.
 
29) 五島雄一郎:新版処方計画法:脂質低下剤, 綜合臨牀.24:191, 1975.
 

8. リポ蛋白欠損症

P.224 掲載の参考文献
1) Fredrickson, D.S., Gotto, A.M.& Levy, R.I.:Familial lipoprotein defficiency.In;The metabolic basis of inherited disease (ed.by Stanbury, J.B, Wyngaarden, J.B.& Fredrickson, D.S.).3rd ed., p.493, Mc Graw-Hill, New York 1972.
 
2) Herbert, P.N., Gotto, A.M.& Fredrickson, D.S.:Familial lipoprotein deficiency.In;The metabolic basis of inherited disease (ed.by Stanbury, J.B, Wyngaarden, J.B, & Fredrickson, D.S.), 4th ed.,p.544, Mc Graw-Hill, New York, 1978.
 
3) Fredrickson, D.S.:Clinical staff conference.Tangier disease.Ann.Intern.Med.55:1016, 1961.
 
4) Schaefer, E.J, Blum, C.B., Levy, R.I., Jenkins, L.L, Alaupovic, P., Foster, D.M.& Brewer, H.B.:New Engl.J.Med., 299:905, 1978.224
 
P.242 掲載の参考文献
1) Sperry, W.M.:J.Biol.Chem., 111:467, 1935.
 
2) Le Breton, E., Pantaleon, J.P.:Arch.Sci.Physiol., 1:199, 1947.
 
3) Glomset, J.A., Parker, F., Tjaden, M.and Williams, R.H.:Biochim.Biophys.Acta, 58:398, 1962.
PubMed
4) Glomset, J.A.:Biochem.Biophys.Acta, 65:128, 1962.
PubMed
5) Glomset, J.A.:J.Lipid Res., 9:155, 1968.
PubMed
6) Osuga, T.and Portman, D.W.:Amer.J.Physiol., 220:735, 1971.
 
7) Glomset, J.A.and Kaplan, D.M:Biochim.Biophys.Acta, 98:41, 1965.
PubMed
8) Glomset, J.A., Janssen, E.T., Kennedy, R.and Dobbins, J.:J.Lipid Res., 7:639, 1966.
 
9) Fielding, C.J.and Fielding, P.E.:FEBS Lett., 15:355, 1971.
PubMed
10) Marcel, Y.L.and Vezina, C.:J.Biol.Chem., 248:8254, 1973.
PubMed
11) Lacko, A.G., Varma, K.G., Rutenberg, H.L.and Soloff, L.A.:Scand.J.Clin.Lab.Invest.,33 suppl.,137:29,1974.
 
12) Albers, J.J., Cabana, V.G.and Stahl, Y.D.B.:Biochemistry, 15:1084, 1976.
 
13) Stokke, K.T.and Norum, K.R.:Scand.J.Clin.Lab.Invest., 27:21, 1971.
PubMed
14) Blomhoff, J.P.:Scand.J.Clin.Lab.Invest., 33 suppl., 137:35, 1974.
 
15) Glomset, J.A.and Wright, J.L.:Biochim.Biophys.Acta, 89:266, 1964.
PubMed
16) Akanuma, Y.,.Kuzuya, T., Hayashi, M., Ide, T.and Kuzuya, N.:Europ.J.Clin.Invest., 3:136, 1973.
PubMed
17) Marcel, Y.L.and Vezina, C.:Biochim.Biophys.Acta, 306:467, 1973.
 
18) Jones, D.P., Sosa, F.R., Shartsis, J., Shak, P.T., Skromak, E.and Beker, W.T.:J.Clin.Invest., 50:259,1971.
 
19) Mahley, R.W., Hamilton, R.L.and Lequire, V.S.:J.Lipid Res., 10:433, 1969.
PubMed
20) Barter, P.J.:J.Lipid Res., 15:11, 1974.
PubMed
21) Akanuma, Y.and Glomset, J.A.:J.Lipid.Res., 9:620, 1968.
 
22) Goodman, Dew.S.l J.Clin.Invest., 43:2026, 1964.
 
23) Goodman, Dew.S.and Shiratori, T.:J.Lipid Res., 5:307, 1964.
 
24) Hamilton, R.L., Williams, M.C., Fielding, C.J.and Havel, R.J.:J.Clin.Invest., 58:667, 1976.
PubMed
25) Glomset, J.A., Norum, K.R., Nichols, AV., Forte, T., King, W.C., Albers, J., Mitchel, C.D., Applegate, K.R.and Gjone, E.:Scand.J.Clin.Lab.Invest., 33 suppl., 137:165, 1974.
 
26) Eisenberg, S.and Levy, R.I.:Adv.Lipid Res., 13:1, 1975.
 
27) Marcel, Y.L.and Vezina, C.:Scand.J.Clin.Lab.Invest.33 suppl., 137:45, 1974.
 
28) Glomset, J.A.:Adv.Lipid Res., 11:1, 1973.
 
29) Norum, K.R.and Gjone, E.:Scand.J.Clin.Lab.Invest., 20:231, 1967.
 
30) Utermann, G., Schoenborn, W., Langer, K.H.and Dieker, P.:Human Genetik, 16:295, 1972.
 
31) Chevet, D.,Ramee, M.P., Pogamp, P.L, Thomas, R., Garre, G.and Alcindor, L.D.:Kidney International,10:185,1976.
 
32) Bron, A.J., Lloyd, J.K.and Fosbrooke, A.S.:Lancet, 1, 928, 1975.
PubMed
33) Iwamoto, A., Naito, C., Teramoto, T., Kato, H., Kako, M., Kariya, T., Shimizu, T., Oka, H.& Oda, T.:Acta Med.Scand., 204:219, 1978.
PubMed
34) Teisberg, P.and Gjone, E.:Ann.Hum Genet., 38, 327, 1975.
PubMed
35) Gjone, E.:Scand.J.Clin.Lab.Invest.33 suppl., 137:73, 1974.
 
36) Naito, C., Teramoto, T., Kato, H., Watanabe, T., Yamanaka, T.& Iwamoto, A.:Scand.J.Clin.Lab.Invest., 38:Suppl.150:168, 1978.
 
37) Ritland, S.and Gjone, E.:Clin.Chim.Acta.59:109, 1975.
PubMed
38) Forte, T., Norum, K.R., Glomset, J.A.and Nichols, A.V.:J.Clin.Invest., 50:1141, 1971.
PubMed
39) Gjone, E., Torvik, H.and Norum, K.R.:Scand.J.Clin.Lab.Invest., 21:327, 1968.
 
40) Gjone, E., Javitt, N.B., Bromhoff, J.P.and Fausa,O.:Acta Med.Scand., 194:377, 1973.
 
41) Manzato, E., Felin, R., Baggio, G., Walch, S., Neubeck, W.and Seidel, D.:J.Clin.Invest., 57:1248, 1976.
 
42) Alaupovic, P., McConathy, W.J., Curry, M.D.and Magnani, H.N.:Scand.J.Clin.Lab.Invest.33 suppl,137:83, 1974.
 
43) Horven, I.:Scand.J.Clin.Lab.Invest.33 suppl., 137:89, 1974.
 
44) Myhre, E., Gjone, E., Flatmark, A.and Hovig, T.:Nephron., 18:239, 1977.
PubMed
45) Norum, K.R.and Gjone, E.:Scand.J.Clin.Lab.Invest., 22:94, 1968.
PubMed
46) 寺本民生, 内藤周幸, 岩本愛吉, 山中健, 加藤泰一:Proc.J.C.B.L, 19:207, 1977.
 
47) Greten, H., DeGrella, R., Klose, G., Rascher, W., DeGennes, J.L.& Gjone, E.:J.Lipid Res., 17:203, 1976.
 
48) Norum, K.R., Glomset, J.A., & Gjone, E:The Metabolic Basis of Inherited Disease (Stanbury, J.B., Wyngaarden, J, B.& Fredrickson, D.S., eds.), 3rd ed., McGraw-Hill, New York, p.531, 1972.
 
49) Gjone, E., Norum, K.R.& Glomset, J.A.:The Metabolic Basis of Inherited Disease (Stanbury, J.B., Wyngaarden, J.B.& Fredrickson, D.S., eds.), 4th ed., McGraw-Hill, New York, p.589, 1978.
 
50) Blomhoff, J.P., Holme, R., Sauar, J.& Gjone, E.:Scand.J.Clin.Lab.Invest., 38:Suppl.150:177, 1978.
 
51) Stokke, K.T., Bjerve, K.S., Blomhoff, J.P., Oysters, B., Flatmark, A., Norum, K.R.and Gjone, E.:Scand.J.Clin.Lab.Invest., 33 suppl., 137:93, 1974.
 
52) 武藤泰敏, 高橋善弥太:肝臓, 12:630, 1971.
 
53) Simon, J.B., Kepkay, D.L.and Poon, P.:Gastroenterology, 66:539, 1974.
 
54) 赤沼安夫:日内会誌, 63:1149, 1974.
 
55) Scanu, A.M., Aggerbeck, L.P., Krusk, A.W., Lim, C.T.and Kayden, H.J.:J.Clin.Invest., 53:440, 1974.
 
56) Assmann, G., Schmitz, G., Adler, K., Heckers, H.and Oette, K.:The IVth international symposium on Atheresclerosis, Tokyo, Aug., 24-28, 235, 1976.
 
57) Scherer, R.and Bauel, G.R.:Klin.Wschr, 51:1059, 1973.
 
58) Clifton-Bligh, P., Nestel, P.J., Whyte, M.H.and Phil, D.:N.Engl.J.Med., 286:567, 1972.
 

9. リピドーシス, ムコポリサッカリドーシス

P.273 掲載の参考文献
1) Wenger, D.:Defects in metabolism of lipids.In;Nelson Textbook of Pediatrics (11th ed.) P.556, W.B.Saunders Co.Philadelphia, 1979.
 
2) Herbert, P.N., et al.:Disorders characterized by evidence of abnormal lipid metabolism.In;The metabolic basis of inherited disease (4th ed.) p.544, McGraw-Hill, Inc.New York, 1978.
 
3) Bernsohn, J.& Grossman, H.J.:Lipid storage diseases, Academic Press, New York, 1971.
 
4) Volk, BW.& Aronson, S M:Sphingolipids, sphingolipidoses and allied disorders (Advances in Experimental Medicine and Biology, vol.19), Plenum New York, 1972.
 
5) Hers, H.G.& van Hoof, F.:Lysosomes and storage diseases, Academic Press, New York, 1973.
 
6) Volk, B.W.& Schneck, L.:The gangliosidoses, Plenum Press New York, 1975.
 
7) Volk, B.W.& Schneck, L:Current trends in sphingolipidoses and allied disorders (Advances in Experimental Medicine and Biology, vol.68), Plenum, New York, 1976.
 
8) 中尾亨 (編):リピドーシス, 小児医学vol.8, No.6, 1975.
 
9) Gatt, S., Freysz, L.& Mandel, P.:Enzymes of lipid metabolism (Advances in Experimental Medicine and Biology, vol.101), Plenum, New York, 1978.
 
10) 吉田久他 (編) 小児内分泌・代謝異常-検査の進め方と治療の実際-金原出版, 1977.
 
11) Canz, M.& Gehler, J.:The mucopolysaccharidoses;Inborn errors of glycosaminoglycan catabolism.Hum.Genet.32:233, 1976.
 
12) McKusick, V.A., Neufeld, E.F.& Kelly, T.E.:The mucopolysac charide storage diseases.In;The metabolic basis of inherited disease (4th ed.) p.1282, McGraw-Hill, Inc.New York, 1978.
 
13) Bartsocas, C., Grobe, H., van de Kamp, J.J.P., von Figura, K., Kresse, H., Klein, U.& Giesberts, M.A.H.:Sanfilippo type C disease:Clinical findings in four patients with a new variant of mucopolysaccharidosis III.Eur.J.Pediatr.130:251, 1979.
 
14) McKusick, V.A.:Heritable Disorders of connective tissue.(4 th ed.), p.521, C.V.Mosby Co., Saint Louis, 1972.
 
15) Dorfman, A.& Matalon, R.:The mucopolysaccharidoses (a review), Proc.Nat.Acad.Sci.USA, 73:630, 1976.
PubMed
16) Rampini, S.:Klinik der Mucopolysaccharidosen, Stutgart:Ferdinand Enke Verlag, 1976.
 
17) 折居忠夫:結合組織の代謝と異常, 現代小児科学大系年刊追補75-C, p.2, 中山書店, 1976.
 
18) Spranger, J.W., Langer, L.O.& Wiedemann, H.-R.:Bone dysplasias; An atlas of constitutional disorders of skeletal development, W.B.Saunders Co., Philadelphia, 1974.
 
19) Spranger, J.:Systemic mucopolysaccharidoses,.:In;Ergebnisse der inneren Medizin und Kinderheilkunde, p.165, Springer Verlag, 1972.
 
20) 折居忠夫:Storage diseaseにみられる骨格系の異常, 脳神経31:455, 1979.
 

書評

最近チェックした商品履歴

Loading...